Loading stocks --

BOP receives PKR20bn first equity tranche from Govt of Punjab; IMS research highlights CAR rise & EPS impact.

Yusra Beg
Stock ImpactPositive

The Bank of Punjab (BOP PA) - Equity Injection & Financial Impact

Intermarket Securities research review on BOP receiving the first PKR20bn equity tranche from the Government of Punjab.

Report Overview

According to Intermarket Securities, The Bank of Punjab (BOP PA) has received PKR20bn from the Government of Punjab (GoP) as the first tranche of an approved equity injection of up to PKR30bn. BOP will issue 523.56mn new shares to GoP at PKR38.20/sh via other than right issue. Out of this, PKR15.6bn was already held as share deposit money as of Sep’26, with a fresh cash injection of c.PKR4.4bn. The remaining PKR10bn will add another c.261.8mn shares.

Capital Adequacy Ratio (CAR) Improvement

Excluding share deposit money, consolidated CAR stood at 12.43% (CET-1: 8.88%) at end-Sep’26, versus the SBP minimum of 11.5%. Post injection, CET-1 and CAR rise to 10.65% and 14.17% with the PKR20bn, and to 11.52% and 15.02% with the full PKR30bn.

Financial Highlights

ParameterPre-injection (30-Sep-26)Post - PKR20bnPost - PKR30bn
Outstanding shares (mn)3,271.63,795.14,056.9
Govt. of Punjab shareholding57.5%63.3%65.7%
CET-1 ratio*10.34%10.65%11.52%
Total CAR13.89%14.17%15.02%
NPAT (9MCY26 annualized)19,06020,18820,752
EPS (PKR)5.835.325.12
EPS (% change vs. current)--8.7%-12.2%
BVPS (PKR)31.1332.1032.49

Earnings & Dilution Impact

While the equity injection lifts absolute earnings, it is near-term EPS-dilutive due to a 24% increase in outstanding shares, leaving earnings c.9% lower post first tranche and c.12% lower post full injection. However, issuing new shares at PKR38.20 represents a 22% premium to the last close. The post-issue price is expected to be c.PKR32.19 after this tranche (+3.1%) and c.PKR32.58 after full injection (+4.3%).

Catalysts

The injection aligns with GoP's STEP Financing under the c.PKR2tn PIVOT plan launched in Oct’26, offering PKR300bn of concessional financing across 463 projects. BOP is well-positioned to originate a large share of this lending.

Risks

  • Asset quality issues on directed lending.
  • Dilution without growth.
  • Sovereign concentration risk.

Conclusion

Earnings recovery depends on BOP's ability to successfully deploy capital into balance-sheet growth near its CY26f ROE of 18%. Investors should evaluate risks and consult professionals before trading.